 |
|
|
| |
EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany |
| |
| |
- Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: original slide presentation at EASL April 2011 Proof of Concept that SVR is Achievable Without Peg/RBV - 4/11 null responder patients achieved SVR w/o Peg/Rbv, with only BMS-790052 (NS5A inhibitor) + BMS-650032 (protease inh)
- (02/03/12)
- The Pharmacokinetic Interaction Between Methadone and the Investigational HCV Protease Inhibitor Telaprevir - (12/07/11)
- Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment - (05/20/11)
- Increasing & Peaking Cirrhosis, Decompensated Cirrhosis & HCC(liver cancer) in UK Projected - (05/07/11)
- EASL HCV Clinical Practice Guidelines - (05/07/11)
- New Approach in HBV & HCV: Gilead's TLR 7 Agonist GS-9620 at EASL - (04/09/11)
- Cost Benefit Analysis of Response Guided Therapy: Dynamic Disease Markov Modeling for Patients with Chronic Hepatitis CVirus (HCV) by Fibrosis Stages - (04/09/11)
- Burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes - (04/09/11)
- EASL Telaprevir Report (coinfection too) - (04/09/11)
- New HCV Drugs at EASL - (04/19/11)
- Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies - (04/18/11)
- Boceprevir at EASL - (04/18/11)
- Pharmacokinetics, Safety and Tolerability of the HCV NS5A Inhibitor ABT-267 Following Single and Multiple Doses in Healthy Adult Volunteers - (04/18/11)
- Utility of Historical Data Compared to Lead-In Response in Predicting Sustained Virologic Response in Nonresponders and Relapsers to Peginterferon/Ribavirin When Retreated With Boceprevir+Peginterferon Alfa-2b/Ribavirin - (04/18/11)
- Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA)
Assessments in Patients with Chronic Hepatitis B (CHB) - (04/18/11)
- High Sustained Virologic Response Among Genotype 1 Previous Non-responders and Relapsers to Peginterferon/Ribavirin when Re-treated With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin - (04/18/11)
- NEPTUNE STUDY: ON-TREATMENT HBsAg LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBeAg-POSITIVE PATIENTS - (04/13/11)
- Baseline Genotype And HBsAg Were Found To Have Significant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment - (04/13/11)
- Anemia & Telaprevir - (04/13/11)
- Highest Rates of Response at Week 72 of the NEPTUNE Study are Achieved with Peginterferon Alfa-2a 180 μg for 48 weeks - (04/13/11)
- Telaprevir Week 4 Response Predicts Outcome (SVR) - (04/13/11)
- Gilead's HCV Pipeline Unveiled at EASL - (04/13/11)
- Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1a/1b When Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin: SVR rates among patients with G1b virus were consistently higher compared with G1a patients in both SPRINT-2 and RESPOND-2 - (04/12/11)
- Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2b)/Ribavirin in HCV (GT1)-Infected Subjects - (04/12/11)
- Overall Safety Profile of Boceprevir Plus Peginterferon Alfa-2b/Ribavirin - (04/12/11)
- Anemia During Treatment With Peginterferon Alfa-2b/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous Treatment-Failure Patients - (04/12/11)
- Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin Reduces Treatment Duration in Previously Untreated and Previous-Treatment-Failure Patients With HCV Genotype 1 - (04/12/11)
- SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV - (04/11/11)
- Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 - (04/11/11)
- A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189, a Nucleotide Polymerase Inhibitor, in Healthy Subjects - (04/11/11)
- No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects - (04/11/11)
- Idenix NS5A HCV replication inhibitors with low
picomolar, pan-genotypicin vitro antiviral activity - (04/11/11)
- CHARACTERIZATION OF NOVEL, HIGHLY POTENT NS5A INHIBITORS WITH QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN HCV CHIMERIC ANIMAL MODEL Intermune Gilead - (04/11/11)
- GNS-227: A New Potent and Selective (2nd Gen)
HCV NS3 Protease Inhibitor With a High Genetic Barrier to Resistance - (04/11/11)
- ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS - (04/11/11)
- Mechanisms of isolated unconjugated hyperbilirubinaemia
induced by the HCV NS3/4A protease inhibitor BI 201335 - (04/11/11)
- PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1 INFECTION - (04/11/11)
- CHARACTERIZATION AND IDENTIFICATION OF PPI-437, PPI-668 AND PPI-833 AS POTENT AND SELECTIVE HCV NS5A INHIBITORS WITH ACTIVITY AGAINST ALL HCV GENOTYPES - (04/11/11)
- BI 201335 pharmacokinetics and early effect
on viral load in HCV genotype-1 patients - (04/11/11)
- Four-week Therapy With Peginterferon Alfa-2b/Ribavirin Effectively Predicts Sustained Virologic Response in Previously Untreated and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin - (04/09/11)
- NOVEL, POTENT, PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITORS WITH A HIGH BARRIER TO RESISTANCE from Roche/Intermune - (04/09/11)
- Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (IL28B affect-see bargraph inside) - (04/09/11)
- BMS-650032, an NS3 Inhibitor (protease), in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Infection - (04/08/11)
- Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin - (04/08/11)
- In vitro profiling of GSK2336805, A Potent and Selective Inhibitor of HCV NS5A - (04/07/11)
- Preclinical Characterization of GSK2485852A, a Novel HCV Polymerase Inhibitor - (04/07/11)
- Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees - (04/07/11)
- Anti-Viral Efficacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection - (04/07/11)
- Low prevalence of danoprevir resistance identified in genotype 1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus peginterferon alfa-2a (40KD)/ribavirin for 12 weeks - (04/06/11)
- BMS-766, a Novel HCV NS5A Inhibitor With Enhanced Resistance Coverage - (04/06/11)
- Three-Day, Dose-Ranging Study of the HCV NS5A Inhibitor GS-5885 - (04/06/11)
- A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection - (04/06/11)
- GS-6620: A Liver Targeted Nucleotide Prodrug with Potent Pan-Genotype Anti-Hepatitis C Virus Activity In Vitro - (04/06/11)
- Emergence and Persistence of NS5B Mutations Following Combination Treatment with Tegobuvir (GS-9190) plus Standard of Care--Long-Term follow-Up from the Phase 2b Study GS-US-196-0103 - (04/06/11)
- Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451 - (04/06/11)
- GS-6620, A Novel Anti-Hepatitis C Virus Nucleotide Prodrug, Has A High In Vitro Barrier To Resistance - (04/06/11)
- PSI-352938, A Novel Purine Nucleotide Analog, Exhibits Potent Antiviral Activity and No Evidence of Resistance in Patients with HCV Genotype 1 Over 7 Days - (04/06/11)
- Nonclinical and Cross-genotypic Profiles of GS-9669, a Novel HCV NS5B Non-nucleoside Thumb Site II Inhibitor - (04/06/11)
- Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist - (04/06/11)
- A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects - (04/06/11)
- Genotypic and Phenotypic Characterization of HCV Resistance From a Multiple Dose Clinical Trial of GS-9451, a Novel NS3 Protease Inhibitor - (04/06/11)
- HCV Drug Resistance - (04/06/11)
- Nucleotide Inhibitor Resistance Selections Using GT2a Infectious Virus: PSI-7851 and GS-6620 Select for A Novel Resistance Pathway Including Substitutions of M289V/L Followed By S282T - (04/06/11)
- Characterization of Viral Resistance Mutations In Genotype 1 HCV Patients Receiving Combination Therapy with a Protease Inhibitor and a Polymerase Inhibitor with or without Ribavirin - (04/06/11)
- Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-333 - (04/05/11)
- Adherence To Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C-Genotype 1 Previously Untreated and Peginterferon/Ribavirin Treatment-Failure Patients Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (patients with >80% adherence to all dosing achieved 90% cure rates. My guess is if adherence is 100% SVR rates will be higher) - (04/05/11)
- Four-Week Treatment with GS-9256 and Tegobuvir (GS-9190) +/- RBV +/- PEG, Results in Enhanced Viral Suppression on Follow-up PEG/RBV Therapy, in Genotype 1a/1b HCV Patients - (04/05/11)
- Genotypic and Phenotypic Characterization of NS3 Variants Selected in
HCV-Infected Patients Treated with ABT-450 - (04/05/11)
- Characterization of Virologic Escape in HCV Genotype 1 Null Responders Receiving a Combination of the NS3 Protease Inhibitor BMS-650032 and NS5A Inhibitor BMS-790052 - (04/05/11)
- ABT-450/Ritonavir (ABT-450/r) Combined with Pegylated Interferon Alpha-2a and Ribavirin After 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-naïve Subjects: 12-Week Interim Efficacy and Safety Results - (04/04/11)
- Boehringer Ingelheim's Lead Hepatitis C Compound Moves into Phase 3 - the First Within the BI HCV Portfolio - (04/04/11)
- Merck, J&J's New Hepatitis C Treatments Fetch $31,000 in France - (04/04/11)
- Anemia had No Effect on Efficacy Outcomes in Treatment-naïve Patients Who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies - (04/04/11)
- Positive Phase 2 results reported with Boehringer Ingelheim's investigational HCV protease inhibitor in both previously treated and untreated patient - (04/04/11)
- TMC435 HCV Protease - (04/04/11)
- Hepatitis C Treatment In France: three-to four-fold increase between now and 2012 is anticipated in the number of patients treated in hospital for HCV genotype 1 infection (the most common in France) - (04/04/11)
- Brief Recap Report from EASL Liver Conference in Berlin: state of HCV Now- policy, treatment, access - (04/04/11)
- Anemia had No Effect on Efficacy Outcomes in Treatment-naïve Patients Who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies - (04/03/11)
- BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN - (04/03/11)
- Evolution of Treatment-Emergent Variants in Telaprevir Phase 3 Clinical Trials - (04/03/11)
- Telaprevir Substantially Improved SVR Rates Across All IL28B Genotypes in the ADVANCE Study - (04/03/11)
- Therapeutic HCV Vaccine - (04/03/11)
- Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients - BMS press release - (04/03/11)
- First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial - (04/03/11)
- Pegylated Interferon-Lambda (PegIFN-λ) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12 - (04/03/11)
- HCV Cured With out Peginterferon/ribavirin with 2 oral HCV drugs BMS790052+BMS650032: Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: "HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052+BMS650032" - (04/02/11)
- The New England Journal of Medicine (NEJM) Publishes Pivotal Studies Showing Merck's Investigational Medicine VICTRELIS (boceprevir) in Combination Therapy Significantly Increased SVR In Patients with Chronic HCV Genotype 1 Who Failed Previous Treatment or Who Were New to Treatment Compared to Control - (04/01/11)
- Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon alpha-2a and Ribavirin in the PILLAR Study - (04/01/11)
- Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-naïve Patients Regardless of Race or Ethnicity - (04/01/11)
- IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR COMBINATION THERAPY - (04/01/11)
- Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of SPRINT-2 and RESPOND-2 Studies - (04/01/11)
- PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in Treatment-naïve Patients with HCV GT2 or GT3 - (04/01/11)
- Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders - (04/01/11)
- SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic genotype-1 HCV infection - (04/01/11)
- SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1 patients with nonresponse to PegIFN/RBV - (04/01/11)
- The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis - (04/01/11)
- Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study - (04/01/11)
- VICTRELIS (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control - (04/01/11)
- New Data Analyses with VICTRELIS (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response - (04/01/11)
- REALIZE Trial Final Results: Telaprevir-based Regimen for Genotype 1 Hepatitis C Virus Infection in Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin - (04/01/11)
- First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNα-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects - (03/31/11)
- Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status - (03/31/11)
- Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C - (03/31/11)
- Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful - (03/31/11)
- Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11)
- Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11)
- ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) - (03/31/11)
- PSI-7977 QD Plus PEG/RBV In HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study - (03/31/11)
- 4 New HCV Drugs: 1st SVR Results from NS5A BMS790052; 2 nucleotides in combination PSI938 + PSI7977; cyclophillin inhibitor Debo25; - (03/31/11)
- Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes - (03/31/11)
- Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor - (03/30/11)
- Achillion Announces Positive RVR
Results With ACH-1625 to Treat Chronic Hepatitis C - (03/30/11)
- Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL - (03/30/11)
|
|
| |
|
|
|
|
|
|
